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Abstract
Aim
Intermittent preventive treatment in pregnancy (IPTp) with azithromycin and monthly sulfa-
doxine-pyrimethamine increased the mean child weight, mid-upper arm and head circumfer-
ence at four weeks of age in a rural low-income setting. Now we assess for how long these
gains were sustained during 0–5 years of age.
Methods
We enrolled 1320 pregnant Malawian women in a randomized trial and treated them with
two doses of sulfadoxine-pyrimethamine (control) or monthly sulfadoxine-pyrimethamine as
IPTp against malaria, or monthly sulfadoxine-pyrimethamine and two doses of azithromycin
(AZI-SP) as IPTp against malaria and reproductive tract infections. Child weight, mid-upper
arm circumference, head circumference and weight-for-height Z-score were recorded at
one, six, 12, 24, 36, 48, and 60 months.
Results
Throughout follow-up, the mean child weight was approximately 100 g higher (difference in
means 0.12 kg, 95% CI 0.04–0.20, P = 0.003 at one month; 0.19 kg, 95% CI 0.05–0.33, P =
0.007, at six months), mean head circumference 2 mm larger (0.3 cm, 95% CI 0.1 to 0.5, P
= 0.004 at one month) and the cumulative incidence of underweight by five years of age was
lower (hazard ratio 0.74, 95% CI 0.60 to 0.90, P = 0.002) in the AZI-SP group than in the
control group. The 2 mm difference in the mean mid-upper arm circumference at one month
(0.2 cm, 95% CI 0.0 to 0.3, P = 0.007) disappeared after three years of age. There was no
difference in mean weight-for-height Z-score at any time point.
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Conclusion
In Malawi, IPTp with azithromycin and monthly sulfadoxine-pyrimethamine has a modest, 3-
5-year positive impact on child weight, mid-upper arm circumference and head circumfer-
ence, but not on weight-for-height Z-score.
Introduction
Childhood growth failure is common, especially in sub-Saharan Africa and in southern Asia.
We have previously reported results from the “Lungwena Antenatal Intervention Study”
(LAIS), that suggest that birth and neonatal size can be increased with intensive maternal
infection control during pregnancy[1,2]. We have also shown that the length gain attained
during fetal period is sustained during the first five years of life[3]. Results of the follow-up
study thus suggested that increased length in bone is not lost during childhood. However, the
situation might be different with child weight, mid-upper arm circumference (MUAC) and
head circumference (HC). This is suggested by results from studies using maternal dietary sup-
plementation with energy and/or nutrients, where fetal-period gains have largely been lost
within a year or two after birth[4,5].
The aim of the current study was to determine for how long the gains in child weight,
MUAC and HC obtained during pregnancy are sustained during the five-year follow-up
among children born to mothers treated with monthly SP and two doses of azithromycin as
compared to children born to women in the control group.
Methods
Study design
This study was a five-year follow-up to the LAIS, a single-center, randomized, partially placebo
controlled, outcome assessor-blinded, three-arm clinical trial conducted in rural Malawi[1].
The main outcomes of the original trial were the incidence of preterm delivery, low birth
weight and infant size at one month[1,2]. Primary outcomes of the follow-up study were child
length/height and stunting throughout the five-year follow-up, total developmental score at
five years, and the total number of deaths. These results have been published earlier and they
supported a hypothesis that the provision of AZI-SP rather than two doses of SP during preg-
nancy reduced the incidence and prevalence of childhood stunting, had a positive effect on
child development, and may have reduced postneonatal mortality[3]. This paper reports the
trends in child weight, MUAC and HC in the three study groups during the five-year follow-
up.
Participants and follow-up
Details of the inclusion and exclusion criteria, and randomization are available in the original
trial publication[1]. In brief, we randomly allocated 1320 women to either a control group or
to one of two intervention groups: monthly SP or AZI-SP. Women in the control group
received standard Malawian antenatal care, which at the time of the study included intermit-
tent preventive treatment in pregnancy with SP (three tablets orally, each containing 500 mg
of sulfadoxine and 25 mg of pyrimethamine) twice: at enrollment and between 28–34 weeks of
gestation. At these visits, they also received a placebo in lieu of azithromycin. Women in the
monthly SP group received SP monthly from enrollment until 37 gestational weeks and two
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doses of placebo in lieu of azithromycin. Women in the AZI-SP group received monthly SP
and active azithromycin (two tablets orally, each containing 500 mg of azithromycin) twice: at
enrollment and between 28–34 weeks of gestation. Both human immunodeficiency virus
(HIV) negative and positive mothers were enrolled to the study. Only participants who signed
or thumb-printed an informed consent form were enrolled in the study.
All children received standard Malawian care during follow-up; HIV positive mothers and
their newborns received nevirapine during/immediately after delivery for prevention of
mother-to-child transmission of HIV.
Child anthropometrics were assessed at the study clinic visits at one, six, 12, 24, 36, 48 and
60 months after birth. Anthropometrists measured child weight with a SECA scale (SECA 834,
Chasmors Ltd; reading increment of 10 g), but between 36 and 60 months the weight of some
children was occasionally measured erroneously with a bathroom scale (reading increment of
1 kg; please see analytic strategy below). Anthropometrists measured child length (�24
months) with a length board (Kiddimetre, Raven Equipment Ltd, reading increment of 1 mm)
or height (>24 months) with a Harpenden stadiometre (Holtain Limited, reading increment
of 1 mm). Arm and head circumferences were measured with a non-elastic plastic tape (Lasso-
o tape, Harlow Printing Limited; reading increment of 1 mm). Research personnel assessing
child anthropometrics were different from those who gave the mother the pre-packed study
drugs. Anthropometrists were not involved in data analysis and they remained blinded to the
intervention group allocation throughout the follow-up.
Both the original trial and the follow-up were performed according to Good Clinical Prac-
tice and ethical standards of Declaration of Helsinki. The protocol was approved by the College
of Medicine Research and Ethics Committee, Malawi (original trial on Apr 30, 2003 and the
follow-up on Feb 22, 2006) and the Ethical Committee of Pirkanmaa Hospital District, Finland
(original trial on Apr 29, 2003 and the follow up on May 9, 2006). The trial was registered with
the U.S. National Library of Medicine (http://www.clinicaltrials.gov) with trial identification
NCT00131235 on Aug 17, 2005. Because the trial started enrollment before Jul 1, 2005, when
the registration of clinical trials became a requirement, the trial was not registered before the
start of enrollment[6]. The authors confirm that all ongoing and related trials for this drug/
intervention are registered.
Outcomes
In this paper we report the secondary growth outcomes of the follow-up study that were child
weight, MUAC, and HC at one, six, 12, 24, 36, 48 and 60 months of age. Child size at one
month of age has been reported earlier[2] but we included those results in this manuscript for
consistency and ease of reading the results. Small differences in the results at one month of age
in this manuscript compared to those reported earlier[2] are due to different time frame in
which the measurement was included in the analysis. If the child did not come for a scheduled
study clinic visit, the study team traced and interviewed the caretaker, and completed a struc-
tured verbal autopsy questionnaire in case the child had died. Number of child deaths during
the follow-up have been reported earlier[3]. None of the deaths were judged to be due to the
maternal intervention.
For anthropometric measurements before 24 months of age, we considered data missing if
the actual date of measurement was off by more than one month from the target date. For
anthropometric measurements at or after 24 months of age, we considered data missing if the
actual date of measurement was off by more than two months from the target date.
We calculated age- and sex-standardized weight-for-age Z-score (WAZ), weight-for-height
Z-score (WHZ), MUAC-for-age Z-score (MUACZ) and HC-for-age Z-score (HCZ) using the
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World Health Organization Child Growth Standards[7,8]. Growth standards allow compari-
son of children to a healthy growing population regardless of ethnicity, socio-economic status
and other background information[7]. As per the Standards, MUACZ is available only from
three months of age onwards[7] and there is no WHZ, MUACZ, or HCZ WHO reference for
children of 60 months of age and older[8]. Thus only WAZ could be analyzed for children
measured between 60–62 months and WAZ, WHZ, MUACZ, and HCZ were analyzed for
children measured between 58–60 months. Values below -2 Z-scores were considered under-
weight, wasting, low MUAC, and small HC. Anthropometrics at their original metrics were
analyzed even though reference was not available for conversion to Z-score.
The associations between intervention and outcome variables are primarily shown without
covariate adjustment, as per predefined statistical analysis plan and International guidelines
[9,10] that highlight the importance of adhering to the statistical analysis plan when presenting
main results.
Statistical analysis
The sample size of 440 pregnant women per group was planned to give 80% power at a 5%
level of significance to detect a 40% reduction in the rate of preterm delivery which was the tri-
al’s main hypothesis[1].
Group codes for the study were broken for the analysis of trial’s main hypothesis. Statisti-
cian for this follow-up was different than the one doing the analyses for the main hypothesis.
For this follow-up study the statistician (LH) merged the intervention code with follow-up
data only after data was cleaned, analysis plan written and the syntax for the analysis done with
a mock code. The analysis was based on the principle of intention-to-treat. We conducted sta-
tistical analyses with Stata 13.1 (StataCorp, College Station, USA).
For absolute weight, MUAC, HC, and Z-scores we calculated group means and used least
squares regression to estimate differences between groups. For prevalence of underweight,
wasting, low MUAC, and small HC we calculated percentages and used log-binomial regres-
sion model to estimate risk ratios or used a modified Poisson regression in case the log-bino-
mial regression did not converge[11]. We used competing-risks regression[12] to estimate
cumulative incidence of underweight, wasting, low MUAC, and small HC under the compet-
ing risk of death.
We took intragroup correlation due to twin pregnancies into account by using robust stan-
dard errors for clustered data[13]. To prevent inflated type I errors due to testing between mul-
tiple groups, we began hypothesis testing with a global null hypothesis of no difference
between any groups (Closed Testing Procedure)[14]. Pairwise null hypotheses were rejected
only if the global null hypothesis was also rejected. We rejected a null hypothesis if two-sided
P<0.05.
A number of sensitivity analyses were performed: an analysis with multiple imputation for
missing data for growth outcomes[15]; an analysis with adjustment for maternal malaria at
enrollment, HIV status, height, body mass index, number of previous pregnancies, number of
school years, and child sex, selected based on predefined criteria presented in the statistical
analysis plan; and an analysis with multiply imputed data to replace weight measurements
rounded to the full kilogram. Because no record was made of weight measurements that were
taken with bathroom scales, it was not possible to identify participants with weight rounded
to the nearest kilogram. As a sensitivity analysis, we considered all full kilogram weight mea-
surements recorded at or after 36 months as censored within an interval of ± 0.5 kg of the full
kilogram and used multiple imputation with interval censoring to replace the value. We per-
formed a post-hoc analysis of anthropometric measurements at last time point for which they
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were available by maternal malaria and HIV status. Because of differences in time of last avail-
able measurement, we used Z-scores in this analysis.
Results
Between December 1, 2003 and October 11, 2006 1320 women were enrolled to the study and
randomized to control (436), monthly SP (441) and AZI-SP groups (443). At enrollment the
intervention groups were similar except for small differences in the prevalence of malaria para-
sitemia and mean number of previous pregnancies (S1 Table).
Four mothers were lost to follow-up during pregnancy and 1269 of 1327 (95.6%) babies
were born alive. The last follow-up visit was completed on March 16, 2012. Data was available
from 1040 (82.0%) participants at 24 months and 953 (75.1%) participants at 60 months of age
(Fig 1). Success of follow-up was similar between the intervention groups (Fisher’s exact test
P = 0.44 and P = 0.97 for proportions with anthropometric measurements at 24 and 60
months, respectively). At enrollment the intervention groups had similar maternal back-
ground characteristics except for small differences in the prevalence of malaria parasitemia
and proportion of primiparous women (Table 1 and S1 Table). At birth, mean duration of
pregnancy was longer in the AZI-SP group compared to the control group. Children born to
mothers in the AZI-SP group had higher birth weight compared to those in the control and
monthly SP groups (Table 1).
Maternal background characteristics were mostly similar between children lost to follow-
up by 60 months and those who remained in the study (S2 Table). Duration of pregnancy at
enrollment and at birth was 0.4 weeks shorter among children who remained in the study than
those who were lost to follow up by 60 months of age (P = 0.04 and P<0.01 for duration of
pregnancy at enrollment and at birth, respectively). The proportion of HIV-positive mothers
was lower among children who remained in the study than among those who were lost to
Fig 1. Follow-up of liveborn children. SP = sulfadoxine-pyrimethamine; AZI-SP = intervention group with monthly
SP and two doses of azithromycin.
https://doi.org/10.1371/journal.pone.0216536.g001
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follow-up (P<0.01). Birth weight was lower (P<0.01) and proportion of low birth weight
higher (P = 0.02) among children who were lost to follow-up compared to those who remained
in the study.
The median number of scheduled SP treatments received by the mothers of liveborn babies
was 2 in the control group, 4 in the monthly SP group, and 4 in the AZI-SP group. Women in
the AZI-SP group received a median of 2 azithromycin doses.
The mean absolute weight of children in the study cohort was 7.1 kg at 6 months and 15.4
kg at 60 months, corresponding to a mean WAZ of -0.69 and -1.32, respectively (Fig 2). The
mean WHZ was 0.34 at 6 months and -0.46 at 60 months. The mean MUAC at the respective
time points was 13.4 cm and 15.2 cm, and MUACZ -0.63 and -1.08. The mean HC was 43.1
cm at 6 months and 49.4 cm at 60 months, corresponding to a mean HCZ of 0.21 and -0.65,
respectively.
Mean absolute weight was 74–232 g higher in the AZI-SP group than in the control group
at different time-points during the follow-up. The differences were statistically significant at
one (0.12 kg, 95% CI 0.04–0.20, P = 0.003) and at six months (0.19 kg, 95% CI 0.05–0.33,
P = 0.007) (Fig 3A, S3 Table). After covariate adjustment the mean difference in weight
between the AZI-SP and the control group varied between 81–224 g with statistically signifi-
cant differences at one (0.08 kg, 95% CI -0.01 to 0.16, P = 0.034) and at six months (0.16 kg,
95% CI 0.02 to 0.29, P = 0.023) (S3 Table). Unadjusted and covariate adjusted mean absolute
MUAC was 1–2 mm higher in the AZI-SP group as compared to the control group until 36
months and was equal to the control group from 48 to 60 months (unadjusted difference
between groups at one month 0.2 cm, 95% CI 0.0 to 0.3, P = 0.007) (Fig 3B, S4 Table). Mean
absolute HC was 1–3 mm larger in the AZI-SP group than in the control group throughout the
follow-up (difference between groups at one month 0.3 cm, 95% CI 0.1 to 0.5, P = 0.004) (Fig
3C, S5 Table). After covariate adjustment the mean difference varied between 0–2 mm with
statistically significant differences at one (0.2 cm, 95% CI 0.0 to 0.4, P = 0.018) and at six
months (0.2 cm, 95% CI 0.0 to 0.4, P = 0.048) (S5 Table). Differences between the groups in
Table 1. Baseline characteristics of the participating women at enrollment and infant characteristics at birth for liveborn children, by study group.
Characteristic Control (SP twice) (N = 421),
n (%)
Monthly SP, (N = 418),
n (%)
AZI-SP (N = 430),
n (%)
Maternal characteristics
Age, years, mean (SD) 25 (7) 25 (7) 25 (6)
Gestational age at enrollment, weeks, mean (SD) 20.3 (3.0) 20.0 (3.2) 20.0 (3.0)
Primiparous 104 (24.7%) 101 (24.2%) 88 (20.5%)
HIV positive 46/384 (12.0%) 62/376 (16.5%) 46/385 (12.0%)
Microsopic peripheral blood malaria parasitemia 46/420 (11.0%) 38/418 (9.1%) 25/430 (5.8%)
Infant characteristics
Duration of pregnancy, mean (SD) 38.5 (2.0)
(1 missing data)
38.7 (2.0) 38.9 (1.8)
(3 missing data)
Birth weight, kg, mean (SD) 2.89 (0.47)
(18 missing data)
2.96 (0.48)
(27 missing data)
3.02 (0.45)
(24 missing data)
Low birth weight, <2.5 kg 52/402 (12.9%) 36/391 (9.2%) 32/406 (7.9%)
Small for gestational agea 84/402 (20.9%) 72/389 (18.5%) 67/404 (16.6%)
SP = sulfadoxine-pyrimethamine. AZI-SP = intervention group with monthly SP and two doses of azithromycin. BMI = body-mass index. HIV = human
immunodeficiency virus. Hb = hemoglobin.
a Small for gestational age calculated using INTERGROWTH-21st Project standards for newborn size by gestational age, defined as birthweight-for-gestation-
week < 10th centile.
https://doi.org/10.1371/journal.pone.0216536.t001
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mean WHZ were not consistently in favor of AZI-SP or any other intervention group over
time (Fig 3D, S3 Table). The results were similar after covariate adjustment (S3 Table). Differ-
ences in means between the monthly SP and the control group had the same pattern as the
AZI-SP versus control group but the differences were smaller and statistically not significant
(S1 Fig, S3–S5 Tables). In general, group means of monthly SP were between the mean values
of the AZI-SP and the control groups, but differences between monthly SP and either of the
other groups were not statistically significant (S1 Fig, S3–S5 Tables).
There were no big differences between the groups in the prevalence of underweight, wast-
ing, low MUAC, and small HC (Fig 4, S6 Table). There were no major differences between
unadjusted and covariate adjusted results (S6 Table). Cumulative incidence of underweight by
five years of age was statistically significantly lower in the AZI-SP group compared to the con-
trol group but there were no differences between the groups in the incidence of wasting, low
MUAC and small HC (Fig 5).
Results from the sensitivity analyses with multiple imputed data to control for missing
anthropometric data and to replace weight measurements rounded to the full kilogram, and
covariate adjusted differences in means and risk ratios were consistent with those from the pri-
mary analyses (S3–S6 Tables). There were no differences in mean child WAZ, WHZ, MUACZ
and HCZ between children whose mothers were HIV negative and HIV positive at enrollment
(S7 Table). Among children whose mothers were malaria positive at enrollment, HCZ was
0.29 (P = 0.004) Z-scores lower compared to those whose mothers were malaria negative at
enrollment. There were no differences in WAZ, WHZ and MUACZ (S7 Table).
Fig 2. Mean weight-for-age Z-score, weight-for-height Z-score, mid-upper arm-circumference-for-age Z-score,
and head circumference-for-age Z-score. At one, six, 12, 24, 36, 48 and 60 months of age, all intervention groups
combined. WAZ = weight-for-age Z-score, WHZ = weight-for-height Z-score, MUACZ = mid-upper arm-
circumference-for-age Z-score, HCZ = head circumference-for-age Z-score.
https://doi.org/10.1371/journal.pone.0216536.g002
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Discussion
In this study, we sought to analyze postnatal sustainability of fetal gains in weight, MUAC and
HC, obtained through an intensified antenatal maternal infection management intervention.
In our sample, children, whose mothers had received monthly SP and two doses of azithromy-
cin during pregnancy rather than two SP doses had approximately 100 g higher mean weight
and 2 mm larger mean head circumference throughout the five-year follow-up than the chil-
dren in the control group. However, the difference was statistically significant only until six
months with weight and until one month with head circumference. The mean MUAC was
approximately 2 mm higher in the AZI-SP group than in the control group from one month
until three years of age, with statistically significant difference at one month, but the difference
disappeared after three years of age. There was no difference in the mean WHZ at any point of
measurement. The cumulative incidence of underweight by five years of age was lower in the
AZI-SP group than in the control group, whereas in the same timeframe there was no differ-
ence between the groups in the point-prevalence or cumulative incidence in wasting, low
MUAC or small head circumference. Mean values of weight, MUAC and HC in monthly SP
group were generally between AZI-SP and the control group but the differences were not sta-
tistically significant with either of the groups.
The validity of the sample findings is supported by random group allocation, broad inclu-
sion criteria, large sample size, comprehensive follow-up, and blinding of the outcome asses-
sors. Potential bias could have been introduced by missing data on anthropometric
measurements and some weight measurements rounded to the nearest full kilogram at 36
months and thereafter. However, we implemented an active tracing system for defaulters and
the random allocation was likely to distribute the non-trial determinants of growth evenly
Fig 3. Differences between groups and 95% confidence interval for AZI-SP vs control in growth outcomes. (A)
Mean weight (kg). (B) Mean mid-upper arm circumference (cm). (C) Mean head circumference (cm). (D) Mean
weight-for-height Z-score (WHZ). SP = sulfadoxine-pyrimethamine; AZI-SP = intervention group with monthly SP
and two doses of azithromycin. � denotes global P<0.05.
https://doi.org/10.1371/journal.pone.0216536.g003
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between the study groups. We have no record of participants who were weighed with bath-
room scale at 1 kg increment but because the anthropometrists doing the measurements were
blinded to the group allocation of the mothers, we believe this occasional use of bathroom
scale was randomly allocated between intervention groups. Also, random measurement error
in the outcome variable does not affect the estimate but is reflected in the standard error of the
estimate, and can thus lead to under-estimation but not over-estimation of the statistical sig-
nificance in difference between groups[16]. Furthermore, the baseline characteristics of those
lost to follow-up and those who remained in the study were similar. Hence we believe that
these factors did not bias our conclusions.
Due to the increasing population variance with age[17], intergroup differences in absolute
size that are statistically significant at birth may not be so in older age groups. In the current
sample, difference in weight was no longer statistically significant after six months and differ-
ence in MUAC and head circumference after one month. However, the point-estimates
remained essentially constant for the absolute weight difference from birth to five years, for
MUAC from birth to three years and fell only slightly for head circumference from birth to
five years. Because of the constant inter-group difference, robustness of the results for sensitiv-
ity analyses, and the biological plausibility of the findings, we consider it likely that the popula-
tion differences in weight and in head circumference are sustained beyond 1–6 months even
though the sample differences were not statistically significant at later time points. The small
fetal gains in MUAC in the AZI-SP group were sustained until three years of age but lost there-
after. No differences between the groups in weight-for-height were observed at any measure-
ment point.
Fig 4. Prevalence of underweight, wasting, low mid-upper arm circumference, and small head circumference by
intervention group. At one, six, 12, 24, 36, 48 and 60 months of age. (A) Underweight defined as weight-for-age Z-
score< -2. (B) Wasting defined as weight-for-height Z-score (WHZ)< -2. (C) Low mid-upper arm circumference
(MUAC) defined as MUAC-for-age Z-score< -2. (D) Small head circumference (HC) defined as HC-for-age Z-score
< -2. SP = sulfadoxine-pyrimethamine; AZI-SP = intervention group with monthly SP and two doses of azithromycin.
� denotes P<0.05 between AZI-SP and the control group.
https://doi.org/10.1371/journal.pone.0216536.g004
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Although monthly SP has been shown to reduce low birth weight by 20% compared to two
doses of SP during pregnancy[18], our results do not support the hypothesis that monthly SP
would have a positive, sustained effect on child growth during the first five years of live. The
mean values of weight, MUAC and HC in the monthly SP group tended to be higher than
those in the control group but remained lower compared to the AZI-SP group, suggesting that
monthly SP alone is not enough to create long-lasting effect on child growth.
We were not able to identify any other studies that would have tested the effect of antibiotic
treatment during pregnancy on child growth after the neonatal period. However, other studies
have tested the hypothesis that a nutritional intervention provided to the mother during preg-
nancy would have positive effects on child size at birth and child growth between one to eight
years after birth[4,5,19–22]. Results of these studies are somewhat contradictory. Two studies
conducted in Burkina Faso[5,20] one study done in Malawi[4] and one in Nepal[21] found
higher weight and/or length at birth or soon after, among children born to mothers who
received dietary supplementation with energy and/or nutrients. However, these differences
were largely lost within 1–8 years after birth. In iron + folic acid + zinc group in the Nepalese
study[21] and in a study done in East Java[22], differences in child size between the groups
were seen only during or at the end of the follow-up, but not at birth. Only one study done in
Nepal had differences between study groups in child weight both at birth and at the end of the
follow-up at 2–3 years of age[19]. Despite the different prenatal interventions used in the stud-
ies, the differences in absolute size between groups in those studies which reported these out-
comes were quite similar after 1–8 years of follow-up as observed in our study[3,19,21,22]
Fig 5. Cumulative incidence of underweight, wasting, low mid-upper arm circumference, and small head
circumference. Under competing risk of death by 60 months of age by intervention group. (A) Underweight defined
as weight-for-age Z< -2. (B) Wasting defined as weight-for-height Z (WHZ)< -2. (C) Low mid-upper arm
circumference (MUAC) defined as MUAC-for-age Z< -2. (D) Small head circumference (HC) defined as HC-for-
age Z< -2. SP = sulfadoxine-pyrimethamine; AZI-SP = intervention group with monthly SP and two doses of
azithromycin; HR = hazard ratio. � denotes P<0.05 between AZI-SP and the control group.
https://doi.org/10.1371/journal.pone.0216536.g005
Impact of antenatal infection treatment on child weight, mid-upper arm circumference and head circumference
PLOS ONE | https://doi.org/10.1371/journal.pone.0216536 May 7, 2019 10 / 14
We have earlier shown that the differences in length between the AZI-SP and the control
group are sustained during the five-year follow-up[3]. Given these earlier and the current
results, it seems possible that fetal weight gain is retained if it is related to linear growth and
bone accrual whereas it is harder to sustain if it represents ponderal growth and fat or other
soft tissue deposition. This is plausible since fat and muscle mass (and hence MUAC and
WHZ) reflect the child’s current nutritional status, whereas attained length (and hence LAZ
and WAZ) is also a function of the child’s earlier growth and environment[23,24].
The current results and those obtained earlier from the same cohort[2,3] suggest that inten-
sified maternal infection control during pregnancy can improve fetal linear growth, resulting
in a sustained effect on infant and child length and possibly weight and HC, but not on
weight-for-height or MUAC. It should be noted, however, that although WHZ and MUAC are
indicators of the child’s current nutritional status, they are far from covering it comprehen-
sively[23]. Furthermore, anthropometric assessment does not in any way measure child devel-
opment or mental and social wellbeing, which are desirable outcomes that have earlier been
associated with nutritional or infection control interventions in pregnancy[3,25–29]. Hence,
although increases in weight, MUAC and HC did not show statistically significant differences
beyond six months, these results should not be interpreted as a discouraging indication that
antenatal infection control or nutritional interventions could not produce long-standing
“healthy growth” in the offspring[30]. It is quite possible that they can–but their assessment
will require outcome measurement that goes beyond traditional anthropometrics.
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